Clinical studies of lorazepam in status epilepticus.
The collective clinical data support the concept that lorazepam is highly effective for a broad range of seizure types, with the major inadequacy being in myoclonus, a seizure type typically highly resistant to other anticonvulsants as well. In addition to its effectiveness, lorazepam appears to have two other major advantages; a prolonged duration of action, which makes frequent or continuous administration unnecessary, and a high degree of freedom from serious side effects involving either the respiratory or cardiovascular system. Although experience at this time is insufficient to allow a firm statement concerning effective concentrations, such concentrations appear readily achievable in most patients with injections of 4 to 5 mg. Lorazepam appears to meet all the requirements of an anticonvulsant useful for treatment of status epilepticus and should prove to be a major drug in the treatment of this condition.
D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008140:Lorazepam / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D008875:Middle Aged; D013226:Status Epilepticus / Q000188:drug therapy* / Q000378:metabolism
D014151:Anti-Anxiety Agents; D008140:Lorazepam